Immunogenicity of a combined schedule of 7-valent pneumococcal conjugate vaccine followed by a 23-valent polysaccharide vaccine in adult recipients of heart or lung transplants

Transplant Infectious Disease

Volumn 13, Issue 5, 2011, Pages 540-544

  Gattringer, R ^a,b   Winkler, H ^a   Roedler, S ^a   Jaksch, P ^a   Herkner, H ^a   Burgmann, H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ELISABETHINEN HOSPITAL   (Austria)

Author keywords

Combined vaccination schedule; Heart transplantation; Lung transplantation; Pneumococcal conjugate vaccine; Pneumococcal polysaccharide vaccine; Pneumococcal vaccination

Indexed keywords

CALCINEURIN INHIBITOR; LYMPHOCYTE ANTIBODY; PNEUMO23; PNEUMOCOCCUS VACCINE; PREDNISONE; RAPAMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HEART TRANSPLANTATION; HUMAN; IMMUNOGENICITY; LUNG TRANSPLANTATION; MALE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, BACTERIAL; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 80053617684     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2011.00628.x     Document Type: Article

References (18)

1. Kumar D, Humar A, Plevneshi A, et al. Invasive pneumococcal disease in solid organ transplant recipients - 10-year prospective population surveillance. Am J Transplant 2007; 7 (5): 1209-1214.
2. Danzinger-Isakov L, Kumar D. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009; 9 (Suppl 4): S258-S262.
3. Blumberg EA, Brozena SC, Stutman P, Wood D, Phan HM, Musher DM. Immunogenicity of pneumococcal vaccine in heart transplant recipients. Clin Infect Dis 2001; 32 (2): 307-310.
4. Sarmiento E, Rodriguez-Hernandez C, Rodriguez-Molina J, et al. Impaired anti-pneumococcal polysaccharide antibody production and invasive pneumococcal infection following heart transplantation. Int Immunopharmacol 2006; 6 (13-14): 2027-2030.
5. de Roux A, Schmole-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46 (7): 1015-1023.
6. Kumar D, Rotstein C, Miyata G, Arlen D, Humar A. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187 (10): 1639-1645.
7. Stoehr GA, Rose MA, Eber SW, Heidemann K, Schubert R, Zielen S. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis. Br J Haematol 2006; 132 (6): 788-790.
8. Lesprit P, Pedrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007; 21 (18): 2425-2434.
9. Molrine DC, Hibberd PL. Vaccines for transplant recipients. Infect Dis Clin North Am 2001; 15 (1): 273-305.
10. Kumar D, Chen MH, Wong G, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis 2008; 47 (7): 885-892.
11. Metersky ML, Dransfield MT, Jackson LA. Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine? Chest 2010; 138 (3): 486-490.
12. Lin PL, Michaels MG, Green M, et al. Safety and immunogenicity of the American Academy of Pediatrics - recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics 2005; 116 (1): 160-167.
13. Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50-80 years. Clin Infect Dis 2009; 49 (9): 1318-1325.
14. Baxendale HE, Davis Z, White HN, Spellerberg MB, Stevenson FK, Goldblatt D. Immunogenetic analysis of the immune response to pneumococcal polysaccharide. Eur J Immunol 2000; 30 (4): 1214-1223.
15. Goldblatt D, Hussain M, Andrews N, et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J Infect Dis 2005; 192 (3): 387-393.
16. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7 (9): 597-606.
17. Dransfield MT, Nahm MH, Han MK, et al. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180 (6): 499-505.
18. Musher DM, Manof SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010; 201 (4): 516-524.